Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of “Hold” from Analysts

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has been assigned an average rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $5.31.

A number of brokerages have weighed in on OMED. Cantor Fitzgerald set a $6.00 price target on Oncomed Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Thursday, January 4th. Finally, HC Wainwright reiterated a “hold” rating and set a $3.00 price target on shares of Oncomed Pharmaceuticals in a report on Friday, March 9th.

How to Become a New Pot Stock Millionaire

Shares of Oncomed Pharmaceuticals stock opened at $2.92 on Friday. Oncomed Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $9.54. The firm has a market capitalization of $111.72, a PE ratio of -2.81 and a beta of 2.18.

Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.59. The business had revenue of $20.64 million for the quarter, compared to analyst estimates of $5.10 million. equities research analysts expect that Oncomed Pharmaceuticals will post -0.96 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Endurant Capital Management LP acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $570,000. Crestline Management LP acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $753,000. Millennium Management LLC grew its stake in shares of Oncomed Pharmaceuticals by 148.7% in the 4th quarter. Millennium Management LLC now owns 543,335 shares of the biopharmaceutical company’s stock valued at $2,228,000 after buying an additional 324,845 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Oncomed Pharmaceuticals in the 4th quarter valued at about $135,000. Finally, Perceptive Advisors LLC grew its stake in shares of Oncomed Pharmaceuticals by 152.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,620,897 shares of the biopharmaceutical company’s stock valued at $10,745,000 after buying an additional 1,582,608 shares during the period. Institutional investors own 53.47% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oncomed Pharmaceuticals Inc (OMED) Receives Average Rating of “Hold” from Analysts” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3298847/oncomed-pharmaceuticals-inc-omed-receives-average-rating-of-hold-from-analysts.html.

Oncomed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Analyst Recommendations for Oncomed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WavesGo Price Hits $0.0298 on Major Exchanges
WavesGo Price Hits $0.0298 on Major Exchanges
DFSCoin Reaches Market Cap of $780,834.00
DFSCoin Reaches Market Cap of $780,834.00
Ceconomy  and GNC  Critical Survey
Ceconomy and GNC Critical Survey
Head to Head Contrast: CSG Systems International  and Mindbody
Head to Head Contrast: CSG Systems International and Mindbody
China Life Insurance  versus Its Rivals Head to Head Analysis
China Life Insurance versus Its Rivals Head to Head Analysis
Analysts Expect BeiGene  Will Post Earnings of -$1.96 Per Share
Analysts Expect BeiGene Will Post Earnings of -$1.96 Per Share


© 2006-2018 Ticker Report. Google+.